PAR

Par Drugs & Chemicals Share Price

₹124.24 -3.8 (-2.97%)

22 Feb, 2025 21:28

SIP TrendupStart SIP in PAR

Start SIP

Performance

  • Low
  • ₹122
  • High
  • ₹134
  • 52 Week Low
  • ₹122
  • 52 Week High
  • ₹348
  • Open Price₹122
  • Previous Close₹128
  • Volume91,931

Investment Returns

  • Over 1 Month -36.96%
  • Over 3 Month -55.85%
  • Over 6 Month -48.19%
  • Over 1 Year -41.79%
SIP Lightning

Smart Investing Starts Here Start SIP with Par Drugs & Chemicals for Steady Growth!

Invest Now

Par Drugs & Chemicals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 9.9
  • PEG Ratio
  • 1.2
  • Market Cap Cr
  • 153
  • P/B Ratio
  • 1.6
  • Average True Range
  • 9.17
  • EPS
  • 12.54
  • Dividend Yield
  • 0
  • MACD Signal
  • -13.12
  • RSI
  • 17.69
  • MFI
  • -

Par Drugs & Chemicals Financials

Par Drugs & Chemicals Technicals

EMA & SMA

Current Price
₹124.24
-3.8 (-2.97%)
pointer
  • stock-down_img
  • Bearish Moving Average 16
  • stock-up_img
  • Bullish Moving Average 0
  • 20 Day
  • ₹164.97
  • 50 Day
  • ₹190.32
  • 100 Day
  • ₹210.66
  • 200 Day
  • ₹221.67

Resistance and Support

126.77 Pivot Speed
  • R3 144.72
  • R2 139.58
  • R1 131.91
  • S1 119.10
  • S2 113.96
  • S3 106.29

What's your outlook on Par Drugs & Chemicals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Par Drugs and Chemicals has an operating revenue of Rs. 101.46 Cr. on a trailing 12-month basis. An annual revenue de-growth of 0% needs improvement, Pre-tax margin of 20% is great, ROE of 16% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 40 which is a POOR score indicating inconsistency in earnings, a RS Rating of 2 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Par Drugs & Chemicals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-14 Quarterly Results & Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2025-01-11 Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2024-10-22 Quarterly Results
2024-08-17 Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2024-08-03 Quarterly Results
Date Purpose Remarks
2021-04-28 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 10/-.

Par Drugs & Chemicals F&O

Par Drugs & Chemicals Shareholding Pattern

73.37%
0%
22.86%
3.77%

About Par Drugs & Chemicals

  • NSE Symbol
  • PAR
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Falgun Vallabhbhai Savani
  • ISIN
  • INE04LG01015

Similar Stocks to Par Drugs & Chemicals

Par Drugs & Chemicals FAQs

Par Drugs & Chemicals share price is ₹124 As on 22 February, 2025 | 21:14

The Market Cap of Par Drugs & Chemicals is ₹152.9 Cr As on 22 February, 2025 | 21:14

The P/E ratio of Par Drugs & Chemicals is 9.9 As on 22 February, 2025 | 21:14

The PB ratio of Par Drugs & Chemicals is 1.6 As on 22 February, 2025 | 21:14

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23